Page 0025

GLOBAL CANCER POLICY-MAKING

its broad-ranging partnerships have helped shaped the Julia Fan is a chartered accountant and PhD candidate working

vaccine markets for HPV. Merck announced lowered tiered on innovative financing for global health at the University of

pricing for its HPV vaccine for GAVI-eligible countries in Cambridge. Her doctoral research focuses on innovation

August 2011 to US$5 per dose. By engaging in a management by global health entrepreneurs. She studies

memorandum of understanding with Rwanda, Merck, as a different business models that push and pull health innovations

biomedical innovator in the discovery and development through discovery, development and delivery. She completed

vaccines, also found an excellent delivery partner (Rwandan her undergraduate education at the University of British

Ministry of Health) to diffuse its biomedical innovation to Columbia with a dual concentration in finance/immunology and

patients in need. In the global health ecosystem, Merck started her career with KPMG’s national health care practice.

requires strong delivery partners with political will and She has worked at the intersection of science and business on

commitment. Rwanda’s Ministry of Health’s partnerships and four continents and is supportive of business models that

combination of existing national infrastructure and external reconcile innovation and access for all. juliafanli@cantab.net

ecosystem resources resulted in shared value being built for

global health ecosystem participants. Professor Richard Sullivan is Director of the King’s Institute of

Cancer Policy. As a member of the Integrated Cancer Centre

Policy perspective Executive he leads external affairs and is also Visiting Professor

The economics of cancer in emerging economies has (Faculty of Medicine) at Universidad Catolica, Santiago de Chile,

traditionally focused in two areas; the first is to understand as well as a senior fellow at the International Prevention

the macro-economics of the cancer burden: trends, drivers, Research Institute, Lyon. He is also a member of the Kings Global

direct health care/out-of-pocket expenses, informal care costs Health and the Marjan Centre for Conflict & Conservation

and productivity costs, and the second around the finance executives. He qualified in medicine at St. Marys Hospital,

models for cancer care systems. Few policy perspectives have, London. He serves on a wide variety of advisory boards,

to our knowledge, attempted to link the value chain of cancer including Charite Comprehensive Cancer Centre Berlin, Irish

technologies in any meaningful way between high-income and Clinical Oncology Group, Pfizer Policy Advisory Board, et al. He

LMI countries. Indeed the prevailing mantra is that there is is past UK Director of the Council for Emerging National

little connection between the techno-economic developments Security Affairs (CENSA) a Washington-based national security

of cancer in high and LMI countries. However, innovation in think-tank where he specialized in bioweapon counter-

cancer research and technologies for care are very much proliferation and the security implications of global health.

needed in LMIC and novel models of financing this are Richard’s research programmes extend from the public policy of

essential if tangible technology transfer is going to diffuse global cancer, to the development of public health systems in

quickly. There is clearly a need for bodies such as the high-risk conflict areas focusing on DR Congo, Afghanistan and

International Monetary Fund and the World Bank to develop Libya. richard.sullivan@kcl.ac.uk

novel regional and high-LMI country institutional models of

technology transfer to address some of the key areas of cancer

control (including women’s cancers) in emerging economies.

References

1. 7.

Sullivan R et al. Delivering Affordable Cancer Care in High Income Countries: a Lancet The Lancet Editorial May 7, 2011 (377) 1544

Oncology Commission. Lancet Oncology 2011 12(10): 923-980 8.

World Health Organziation PDF Report Human papillomavirus and related cancers in

2.

The World Health Report 2010: Health Systems Financing, the path to universal Rwanda: summary report Sept 15 2010:

coverage. World Health Organization http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/RWA.pdf?CFID=4

3.

Commission on Intellectual Property Rights, I. a. P. H. (2006). Public Health, 087111&CFTOKEN=30464716 - accessed June 24, 2012

9.

Innovation and Intellectual Property Rights Geneva: World Health Organization. Binagwaho, A., Wagner, C., Gatera, M., Karema, C., Nutt, C., & Ngabo, F. (2011).

4.

Hansen, M., & Birkinshaw, J. (2007). The innovation value chain. Harvard Business Achieving high coverage in Rwanda's national human papillomavirus vaccination

Review, 85(6), 121-130. programme. Bulletin of the World Health Organization, 90(8), 623-628.

10.

5.

Wheeler, C. M., Castellsague, X., Garland, S. M., Szarewski, A., Paavonen, J., Naud, P., et Logie, D., Rowson, M., & Ndagije, F. (2008). Innovations in Rwanda's health system:

al. (2012). Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against looking to the future. Lancet, 372(9634), 245-261.

11.

cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year Binagwaho, A., Wagner, C., Gatera, M., Karema, C., Nutt, C., & Ngabo, F. (2012).

end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Achieving high coverage in Rwanda's national human papillomavirus vaccination

Oncology, 13(1), 100-110. programme. Bulletin of the World Health Organization, 90(8), 623-628.

6. 12.

Schiffman, M., & Wacholder, S. (2012). Success of HPV vaccination is now a matter of Ouedraogo, N., Muller, A., & Gerhardus, A. (2011). Human papillomavirus vaccination

coverage. Lancet Oncology, 13(1), 10-12. in Africa. Lancet, 378, 315.

CANCER CONTROL 2013 23

Index

  1. CANCER CONTROL 2013
  2. Page 0002
  3. Page 0003
  4. Page 0004
  5. Page 0005
  6. Page 0006
  7. Page 0007
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Page 0018
  19. Page 0019
  20. Page 0020
  21. Page 0021
  22. Page 0022
  23. Page 0023
  24. Page 0024
  25. Page 0025
  26. Page 0026
  27. Page 0027
  28. Page 0028
  29. Page 0029
  30. Page 0030
  31. Page 0031
  32. Page 0032
  33. Page 0033
  34. Page 0034
  35. Page 0035
  36. Page 0036
  37. Page 0037
  38. Page 0038
  39. Page 0039
  40. Page 0040
  41. Page 0041
  42. Page 0042
  43. Page 0043
  44. Page 0044
  45. Page 0045
  46. Page 0046
  47. Page 0047
  48. Page 0048
  49. Page 0049
  50. Page 0050
  51. Page 0051
  52. Page 0052
  53. Page 0053
  54. Page 0054
  55. Page 0055
  56. Page 0056
  57. Page 0057
  58. Page 0058
  59. Page 0059
  60. Page 0060
  61. Page 0061
  62. Page 0062
  63. Page 0063
  64. Page 0064
  65. Page 0065
  66. Page 0066
  67. Page 0067
  68. Page 0068
  69. Page 0069
  70. Page 0070
  71. Page 0071
  72. Page 0072
  73. Page 0073
  74. Page 0074
  75. Page 0075
  76. Page 0076
  77. Page 0077
  78. Page 0078
  79. Page 0079
  80. Page 0080
  81. Page 0081
  82. Page 0082
  83. Page 0083
  84. Page 0084
  85. Page 0085
  86. Page 0086
  87. Page 0087
  88. Page 0088
  89. Page 0089
  90. Page 0090
  91. Page 0091
  92. Page 0092
  93. Page 0093
  94. Page 0094
  95. Page 0095
  96. Page 0096
  97. Page 0097
  98. Page 0098
  99. Page 0099
  100. Page 0100
  101. Page 0101
  102. Page 0102
  103. Page 0103
  104. Page 0104
  105. Page 0105
  106. Page 0106
  107. Page 0107
  108. Page 0108
  109. Page 0109
  110. Page 0110
  111. Page 0111
  112. Page 0112
  113. Page 0113
  114. Page 0114
  115. Page 0115
  116. Page 0116
  117. Page 0117
  118. Page 0118
  119. Page 0119
  120. Page 0120
  121. Page 0121
  122. Page 0122
  123. Page 0123
  124. Page 0124
  125. Page 0125
  126. Page 0126
  127. Page 0127
  128. Page 0128
  129. Page 0129
  130. Page 0130
  131. Page 0131
  132. Page 0132
  133. Page 0133
  134. Page 0134
  135. Page 0135
  136. Page 0136
  137. Page 0137
  138. Page 0138
  139. Page 0139
  140. Page 0140
  141. Page 0141
  142. Page 0142
  143. Page 0143
  144. Page 0144
  145. Page 0145
  146. Page 0146
  147. Page 0147
  148. Page 0148
  149. Page 0149
  150. Page 0150
  151. Page 0151
  152. Page 0152
  153. Page 0153
  154. Page 0154
  155. Page 0155
  156. Page 0156
  157. Page 0157
  158. Page 0158
  159. Page 0159
  160. Page 0160
  161. Page 0161
  162. Page 0162
  163. Page 0163
  164. Page 0164
  165. Page 0165
  166. Page 0166
  167. Page 0167
  168. Page 0168
  169. Page 0169
  170. Page 0170
  171. Page 0171
  172. Page 0172
  173. Page 0173
  174. Page 0174
  175. Page 0175
  176. Page 0176
  177. Page 0177
  178. Page 0178
  179. Page 0179
  180. Page 0180

powered by PageTiger